Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162751 | 0.98 | HPGD (0.62) | HPGDHTTHCRTR1HCRTR2MEN1 | |
| SCHEMBL4163152 | 0.87 | HRH4 (0.53) | HPGDHTTHCRTR1HCRTR2MEN1 | |
| SCHEMBL2529453 | 0.86 | MEN1 (0.55) | HPGDHTTHCRTR1HCRTR2MEN1 | |
| SCHEMBL28642930 | 0.83 | HPGD (0.52) | HPGDHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL12846473 | 0.83 | HPGD (0.58) | HPGDHTTHCRTR1HCRTR2MEN1 | |
| SCHEMBL12882367 | 0.82 | HCRTR1 (0.47) | HPGDHTTHCRTR1HCRTR2MEN1 | |
| SCHEMBL15306495 | 0.81 | HPGD (0.57) | HPGDHTTHCRTR1HCRTR2MEN1 | |
| SCHEMBL29944128 | 0.81 | TSHR (0.62) | HPGDMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL7899916 | 0.80 | HPGD (0.55) | HPGDHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL21189714 | 0.80 | HPGD (0.58) | HPGDHTTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | HPGD 272/4885HTT 4858/4885HCRTR1 901/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | HPGD 272/4885HTT 4858/4885HCRTR1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.